Маалокс

Маалокс – antiacid means.

Form of release and structure

Dosage forms:

• Chewable tablets: a round ploskotsilindrichesky form, white color, with a facet and an engraving of "Mx" (on 10 pieces in blisters, in a cardboard pack 1, 2 or 4 blisters);
• Suspension for intake: the liquid of white or almost white color reminding milk, with a mint smell (on 250 ml in glass bottles of dark color, in a cardboard pack 1 bottle; on 15 ml in bags (sachet), in a cardboard pack of 30 bags).

Active ingredients of Maaloks:

• Algeldrat (in the form of hydroxide aluminum): in 1 tablet – 0,4 g (0,2 g of aluminum of oxide are equivalent), in 100 ml of suspension – 3,5 g;
• Magnesium hydroxide: in 1 tablet – 0,4 g, in 100 ml of suspension – 4 g.

Auxiliary components:

• Tablets: sodium saccharinate, starch with sucrose (sugar confectionery), sucrose, sorbitol, magnesium stearate, Mannitolum, peppermint fragrance;
• Suspension: sodium saccharinate, Acidum hydrochloricum concentrated 10%, oil of leaves of mint of peppery, citric acid monohydrate, hydrogen peroxide of 30%, methylparahydroxybenzoate, Mannitolum, пропилпарагидроксибензоат sorbitol of 70%, the water purified.

Indications to use

• Aggravation of a peptic ulcer of a stomach and duodenum;
• Aggravation of a chronic gastroduodenit with the normal or increased secretory function;
• Gastroduodenit in an acute form;
• Reflux esophagitis;
• Treatment and prevention of the dispeptic phenomena arising against the background of use of glucocorticosteroids, non-steroidal anti-inflammatory drugs and other medicines;
• Hernia of an esophageal opening of a diaphragm;
• Heartburn, discomfort or pains in the epigastriums, an acid eructation arising at excess alcohol intake, coffee, nicotine or errors in a diet.

Contraindications

For tablets:

• Hypersensitivity to drug components;
• Heavy renal failures.

It is not recommended to take a pill without consultation of the doctor aged up to 12 years.

For suspension:

• Glyukozo-galaktozny malabsorption, deficit of invertase or isomaltase, intolerance of fructose;
• The expressed renal failure;
• Hypophosphatemia;
• Age up to 15 years.

Under regular observation of the doctor it is necessary to apply suspension: the patient with a renal failure (as there is a risk of increase in plasma concentration of aluminum and magnesium, and long reception in high doses (including high therapeutic doses) can cause development of dementia, encephalopathy, microcytic anemia); to the patients with a porphyria who are on a hemodialysis; keeping to a diet with the low content of phosphates (risk of development of phosphatic insufficiency).

With care it is necessary to appoint Maaloks in both dosage forms to patients with Alzheimer's disease; during pregnancy and breastfeeding.

Route of administration and dosage

• Tablets: accept inside, carefully chewing. The recommended dosing: on 1-2 tablets 3-4 times a day in 1-2 hours after meal and before going to bed. At a reflux esophagitis the break between food and reception of tablets should be reduced. Course of treatment no more than 2-3 months. For incidental use the single dose of 1-2 tablets is shown;
• Suspension: it is intended for intake in not dissolved look. Drug in a bag should be kneaded previously carefully fingers of hands. The recommended dosing by the adult and to children is more senior than 15 years: on 15 ml in 1-2 hours after each meal and in case of developing of heartburn or pains in epigastriums. The maximum daily dose – no more than 90 ml. At a reflux esophagitis suspension should be accepted in 0,5-1 hour after food, a peptic ulcer of a stomach – in 0,5 hours prior to food. Course of treatment no more than 2-3 months. At the incidental reception connected, for example, with discomfort after errors in a diet – on 15 ml once. Patients with a renal failure cannot appoint drug to the long period and/or in high doses.

Side effects

• Tablets: at a renal failure and/or against the background of long therapy – increase in content of magnesium and/or aluminum in a blood plasma, encephalopathy, a lack of phosphorus of an organism, an exacerbation of Alzheimer's disease and musculoskeletal pathologies at patients of advanced age;
• Suspension: seldom – diarrhea; at prolonged use of high doses – a hypophosphatemia (is more often at a low-phosphatic diet), a nephrocalcinosis, a hypercalcuria, a hypocalcemia, osteomalacy, osteoporosis, functional disorder of kidneys. At a renal failure: perhaps – a hyporeflexia, increase in level of plasma concentration of aluminum and/or magnesium, development of feeling of thirst, a lowering of arterial pressure; seldom – at long reception of high doses development of dementia, encephalopathy, microcytic anemia is possible.

Besides, in rare instances Maaloks's use causes frustration of the alimentary system in the form of change of flavoring feelings, nausea, locks, vomiting.

Special instructions

Observance of the recommended mode of dosing reduces risk of development of side effects.

It is recommended to observe a break at a concomitant use of Maaloks with other medicines not less than 2, and at a combination to ftorkhinolona – 4 hours.

At a renal failure it is necessary to appoint drug with care.

In need of purpose of tablets children up to 12 years should set the mode of dosing individually, according to clinical indications.

At preservation of symptoms or an aggravation of symptoms from digestive tract after 10 days of reception of suspension, it is necessary to see a doctor for specification of the diagnosis and correction of therapy.

Use of drug for teenagers, during pregnancy and breastfeeding, and also at a renal failure easy and moderate severity should be begun only after consultation of the doctor.

As action of an algeldrat at a low-phosphatic diet can promote development in an organism of insufficiency of phosphorus, it is recommended to provide to the patient food rich with phosphates, especially at long therapy.

Маалокс does not exert impact on ability of patients to control of vehicles and mechanisms.

Medicinal interaction

At non-compliance with a two-hour break between reception, Maaloks's tablets reduce absorption of the following at the same time used drugs: tetracyclines, acetylsalicylic acid (and other salicylates), an atenolola, propranolol, a metoprolol, a diflunisal, chloroquine, digoxin, _H2 blockers - histamine receptors, bisfosfonat, sodium of fluoride, an isoniazid, Ethambutolum, ftorkhinolon, glucocorticosteroids (it is described for dexamethasone and Prednisolonum), a lansoprazola, indometacin, linkozamid, a ketokonazol, left thyroxine of sodium, sodium of polystyrenesulphate, salts of iron, Penicillaminum, fenotiazinovy neuroleptics, a feksofenadin, phosphorus nutritional supplements.

To avoid undesirable interaction of drug from ftorkhinolona having rummaged in reception there should not be less than 4 hours.

At a combination to quinidine increase in level of its concentration in blood serum is possible that can cause quinidine overdose.

Against the background of alkalization of urine under the influence of Maaloks, at simultaneous use of salicylates there is an increase in their excretion to urine.

The accompanying therapy by citrates can promote increase in level of concentration of aluminum in a blood plasma, especially, at patients with a renal failure.

Terms and storage conditions

To store at a temperature up to 25 °C. To protect from children.

Period of validity: chewable tablets – 5 years, suspension for intake – 3 years.